Abstract:The NFYA gene has two main isoforms: NFYA‐L (Long) and NFYA‐S (Short), which differ in their inclusion of exon 3. In clinical practice, AML can be categorized into four groups based on NFYA isoform expression: NFYA‐L low/NFYA‐S high, NFYA‐L high/NFYA‐S high, NFYA‐L low/NFYA‐S low and NFYA‐L high/NFYA‐S low. NFYA splicing patterns significantly affect outcomes for AML patients following intensive chemotherapy, particularly in distinguishing between the NFYA‐L low/NFYA‐S high and NFYA‐L high/NFYA‐S low groups. Summary Aberrant alternative splicing (AS) contributes to leukemogenesis, but reports on the clinical and biological implications of aberrant AS in acute myeloid leukaemia (AML) remain limited. Here, we used RNA‐seq to analyse AS in AML cells from 341 patients, comparing them to healthy CD34+ haematopoietic stem cells (HSCs). Our findings highlight distinct AS patterns in the nuclear transcription factor Y subunit alpha (NFYA) gene, with two main isoforms: NFYA‐L (Long) and NFYA‐S (Short), differing in exon 3 inclusion. Patients with lower NFYA‐L but higher NFYA‐S expression, termed NFYA‐S predominance, displayed more favourable characteristics and better outcomes following intensive chemotherapy, regardless of age and European LeukemiaNet risk classification, compared to those with higher NFYA‐L but lower NFYA‐S expression, termed NFYA‐L predominance. The prognostic effects were validated using The Cancer Genome Atlas cohort. Transcriptome analysis revealed upregulated cell cycle genes in NFYA‐S predominant cases, resembling those of active HSCs, demonstrating relative chemosensitivity. Conversely, NFYA‐L predominant cases, as observed in KMT2A‐rearranged leukaemia, were associated with relative chemoresistance. NFYA‐S overexpression in OCI‐AML3 cells promoted cell proliferation, S‐phase entry and increased cytarabine sensitivity, suggesting its clinical and therapeutic relevance in AML. Our study underscores NFYA AS as a potential prognostic biomarker in AML.

Splicing factor-mediated regulation patterns reveals biological characteristics and aid in predicting prognosis in acute myeloid leukemia

Comprehensive Characterization of the Prognosis Value of Alternative Splicing Events in Acute Myeloid Leukemia.

Clusterization in acute myeloid leukemia based on prognostic alternative splicing signature to reveal the clinical characteristics in the bone marrow microenvironment

Prognostic Alternative Mrna Splicing Signatures and Associated Splicing Factors in Acute Myeloid Leukemia.

Prognostic Alternative Splicing Regulatory Network of Splicing Events in Acute Myeloid Leukemia Patients Based on SpliceSeq Data from 136 Cases

Splicing factors: Insights into their regulatory network in alternative splicing in cancer

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia

RNA splicing alterations induce a cellular stress response associated with poor prognosis in AML

Rna-Seq Profiling Reveals Aberrant Rna Splicing in Patient with Adult Acute Myeloid Leukemia During Treatment

The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome

Study of prognostic splicing factors in cancer using machine learning approaches

The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy

Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia

Alternative Splicing in Myeloid Malignancies

Distinct Splicing Signatures Affect Converged Pathways in Myelodysplastic Syndrome Patients Carrying Mutations in Different Splicing Regulators.

Correlations Between the Characteristics of Alternative Splicing Events, Prognosis, and the Immune Microenvironment in Breast Cancer

Broad de-regulated U2AF1 splicing is prognostic and augments leukemic transformation via protein arginine methyltransferase activation

Clinical and Prognostic Profile of SRSF2 and Related Spliceosome Mutations in Patients with Acute Myeloid Leukemia.

Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features

Alternative Splicing Analysis Showed the Splicing Factor Polypyrimidine Tract-Binding Protein 1 As a Potential Target in Acute Myeloid Leukemia Therapy.

Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy